Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Empagliflozin...

    Empagliflozin decreases on risk Of CV Death and HF hospitalization

    Dr. Prem AggarwalWritten by Dr. Prem Aggarwal Published On 2017-10-19T19:32:57+05:30  |  Updated On 19 Oct 2017 7:32 PM IST
    Empagliflozin decreases on risk Of CV Death and HF hospitalization

    Diabetes has been found to be associated with increased risk of cardiovascular death and heart failure. Diabetic patients get increased incidence of coronary artery disease and acute coronary syndrome. The drugs for control of diabetes are now evaluated more on the basis of their capacity to decrease cardiovascular risk as well as control of hyperglycemia.


    In EMPA-REG OUTCOME, 7020 patients with type 2 diabetes (HbA1c 7–10% and eGFR > 30 mL/min/1.73 m2) and established atherosclerotic cardiovascular disease (CVD) were treated with empagliflozin 10 or 25 mg, or placebo, once daily and followed for a median of 3.1 years.


    Empagliflozin reduced the risk of CV death by 38%, heart failure (HF) hospitalization by 35%, and the composite of CV death and HF hospitalization by 34%. The benefits of empagliflozin were similar in those with (10.1%) and without (89.9%) HF at baseline.


    In the 6314 patients without HF at baseline, the researchers derived the 5-year risk for incident HF using the 9-variable Health ABC HF Risk score [classified as low-to-average (>10%), high (10–20%), and very high (≥ 20%)]. Overall, 67.2% of the population had low-to-average HF risk, 24.2% were at high risk, and 5.1% at very high 5-year HF risk.


    The benefit of treatment with Empagliflozin was apparent across all 3 groups for the endpoint of CV death and HF hospitalization.


    Consistent with the effects seen in the overall trial population, empagliflozin reduced the risk of CV death across the spectrum of HF risk, although the absolute risk reductions were lower in those without HF and less HF risk.


    The researcher concluded that treatment with empagliflozin in patients with diabetes and established CVD reduced the risk for HF hospitalization and CV death across a spectrum of HF risk.


    HF benefits seen with the sodium glucose cotransporter-2 (SGLT2) inhibitors may be “consequent to improved hemodynamics with a reduction of loading of the myocardium.”


    References




    • J Butler, Presenter. ESC 2017 Late-Breaking Clinical Trial: Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME. ESC 2017. 28 AUG 2017.

    • D Fitchett, J Butler, P van de Borne, et al: Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J. 28 Aug 2014. (Published online ahead of print.)


    cardiovascular deathCardiovascular RiskCoronary artery diseasediabetesempagliflozinheart failureHospitalizationHyperglycemia

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Prem Aggarwal
    Dr. Prem Aggarwal

      Dr Prem Aggarwal, (MD, DNB Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder of Medical Dialogues. He is the Chairman of Sanjeevan Hospital in Central Delhi and also serving as the member of Delhi Medical Council

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok